Abstract: This invention pertains to the field of plant extraction and separation technology, and provides a polysaccharide compound with a defined molecular structure that possesses antitumor efficacy and mitigates the toxic side effects of chemotherapy. The polysaccharide compound is intended for the treatment of advanced cancer patients (those who are no longer candidates for surgery, have a life expectancy of only three to six months, and are still eligible for chemotherapy). The molecular formula of the polysaccharide compound is: (C66H110O55)n. The active ingredient, polysaccharide, is obtained through the extraction of effective components from Ganoderma lucidum under high temperature and high pressure. The polysaccharide with this active ingredient, characterized by its water solubility, is readily absorbed by the human body, offers antitumor effects, and has proven efficacy in the prevention of tumor development in humans.

Abstract: This invention pertains to the field of plant extraction and separation technology and provides a polysaccharide compound, GLP-4, with a defined molecular structure, effective in treating emphysema and pulmonary fibrosis, and exhibiting antitumor effects. The molecular formula is: (C162H270O135)n. The polysaccharide compound is obtained by extracting from a residue of Ganoderma lucidum processed with alkaline solution under high temperature and high pressure, followed by column chromatographic separation. The polysaccharide compound features excellent water solubility and is readily absorbed by the human body. The polysaccharide compound shows superior efficacy in treating emphysema and pulmonary fibrosis compared to pirfenidone and is also effective for patients with advanced cancer (those who are no longer surgical candidates, with a life expectancy of only three to six months, and still eligible for chemotherapy).

Abstract: Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: The present application provides GPC2-specific antibodies and antigen binding fragments thereof. A chimeric antigen receptor (CAR) that specifically binds glypican-2 (GPC2) comprising a GPC2-specific antibody, a transmembrane domain, and an intracellular signaling domain. T cells comprising the disclosed CAR constructs can be used for cancer immunotherapy.

Abstract: Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.